Loading...
Market
Primary reason for Rybelsus sales growth in 2025?
2
Resolution / Starting Odds
Cardiovascular benefits • 25%
Increased marketing efforts • 25%
Regulatory approvals • 25%
Other reasons • 25%
Novo Nordisk annual report and market analysis reports
Story
Novo Nordisk's Rybelsus Cuts Cardiovascular Risk by 14% in SOUL Trial
Oct 21, 2024, 10:15 AM
Novo Nordisk's oral semaglutide, marketed as Rybelsus, has demonstrated a 14% reduction in the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes, according to the results of the SOUL trial. The late-stage study, announced on Monday, involved over 9,600 patients with type 2 diabetes and heart or kidney disease. Novo Nordisk plans to file for regulatory approval of a label expansion for Rybelsus in both the US and EU around the turn of the year. The drug, a tablet version of Ozempic, showed significant potential in reducing the risk of heart attacks and strokes, which may drive broader use of the medication.
View original story
Similar markets
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Wegovy • 25%
Zepbound • 25%
Ozempic • 25%
Other • 25%
Anti-ageing • 25%
Weight loss • 25%
Heart disease reduction • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Price competitiveness • 25%
Efficacy and safety profile • 25%
Marketing and distribution • 25%
Regulatory support • 25%
Type 2 Diabetes • 25%
Obesity • 25%
Knee Pain from Osteoarthritis • 25%
Other • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Zepbound • 25%
Wegovy • 25%
Ozempic • 25%
Other • 25%